


RealRate

PHARMACEUTICAL 2019











RealRate

PHARMACEUTICAL 2019



ANAPTYSBIO INC Rank 14 of 363

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of ANAPTYSBIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 256% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	434,216
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,836
Liabilities, Non-Current	0
Other Assets	73,336
Other Compr. Net Income	203
Other Expenses	-192
Other Liabilities	0
Other Net Income	4,874
Other Revenues	5,000
Property and Equipment	1,445
Research and Development	56,196
Selling, General and Administrative Expense	15,526

Output Variable	Value in 1000 USD
Assets	508,997
Liabilities	21,836
Expenses	71,530
Revenues	5,000
Stockholders Equity	487,161
Net Income	-61,656
Comprehensive Net Income	-61,554
Economic Capital Ratio	293%

